Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
Strawn
Matthew N
MN
D000329:Advertising / Q000331:legislation & jurisprudence*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D003249:Constitution and Bylaws; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D004346:Drug Information Services; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D000697:Central Nervous System Stimulants; D008774:Methylphenidate